Eric Valeur
About Eric Valeur
Eric Valeur PhD Biography
Eric Valeur, PhD, serves as the Vice President and Head of Drug Discovery, with over 15 years in the industry. His extensive career includes roles at leading pharmaceutical companies such as Merck-Serono, Novartis, and AstraZeneca. He holds a PhD in organic chemistry from the University of Edinburgh and an MBA from Imperial College London. His work spans a variety of therapeutic areas and drug modalities, marking him as a significant contributor to the field of drug discovery.
Eric Valeur Expertise in Drug Discovery
Eric Valeur boasts extensive expertise in drug discovery, having led projects across multiple therapeutic areas and drug modalities. His proficiency includes small molecules, macrocycles, peptides, oligonucleotides, drug conjugates, and degraders. At AstraZeneca, he built the first New Modalities group in the industry and led a corporate-wide drug discovery transformation project, showcasing his ability to drive innovation and substantial projects.
Eric Valeur Experience at AstraZeneca
During his tenure at AstraZeneca, Eric Valeur made significant contributions by building the first New Modalities group in the industry. He also spearheaded a comprehensive corporate-wide drug discovery transformation project. These roles underscore his leadership in advancing drug discovery methodologies and his influential presence within the company.
Eric Valeur's Educational Background
Eric Valeur's academic qualifications include a PhD in organic chemistry from the University of Edinburgh, alongside an MBA from Imperial College London. This combination of advanced scientific training and business acumen supports his leadership roles and strategic decision-making in the pharmaceutical industry.
Publications and Patents by Eric Valeur
Eric Valeur is a coauthor and coinventor of over 65 publications, patents, posters, and oral presentations. His contributions to the scientific community underline his dedication to advancing pharmaceutical research and his active involvement in disseminating new knowledge and innovations in drug discovery.